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The signaling adaptor p62 is a multidomain protein implicated in the activation of the transcription 
factor NF-κB. Recent findings link p62 activity to the extrinsic apoptosis pathway, and Mathew 
et al. (2009) now show that the modulation of p62 by autophagy is a key factor in tumorigenesis. 
These findings place p62 at critical decision points that control cell death and survival.The intricate signaling network that determines whether cells 
grow, senesce, or die achieves a remarkable degree of speci-
ficity with a relatively small number of signaling molecules. This 
fidelity is possible because of the multidomain protein adapt-
ers that organize signaling traffic (Moscat et al., 2007). One 
such adaptor is p62 (also known as sequestosome-1), which 
was initially isolated as an interacting partner of atypical pro-
tein kinase C (aPKC). Studies employing knockout, transgenic, 
and knockin mice have shown that p62 plays critical roles in a 
number of cellular functions, including bone remodeling, obe-
sity, and cancer (Duran et al., 2004, 2008; Moscat et al., 2006; 
Rodriguez et al., 2006).
In this Minireview, we discuss exciting new observations 
about p62. Recent work reveals that p62 acts as a signaling 
hub through its ability to recruit and oligomerize important sig-
naling molecules in cytosolic speckles to control cell survival 
and apoptosis (Sanz et al., 2000; Jin et al., 2009). In findings 
reported in this issue, Mathew et al. (2009) show that the elimi-
nation of p62 by autophagy suppresses tumorigenesis. These 
discoveries suggest that p62 is a central player in the life and 
death decisions of the cell.
p62 Signaling Complexes and Intracellular Speckles
The structure of p62 reveals a rich potential for interacting part-
ners consistent with its role as a focal point in signal transduction 
(Figures 1A and 1B). Among its many domains, p62 has a PB1 
domain, which is a protein-protein interaction module present 
in other signaling molecules, such as the aPKCs and the polar-
ity protein Par-6. aPKCs and p62 bind each other through their 
PB1 domains, and this binding is implicated in the activation of 
the transcription factor NF-κB downstream of cell stimulation by 
interleukin 1 (IL-1), RANK ligand (RANKL), or nerve growth fac-
tor (NGF) (Sanz et al., 2000; Duran et al., 2004). Additionally, the 
PB1 domain of p62 also facilitates its oligomerization, which is 
thought to be critical for its cellular function (Moscat et al., 2006, 
2007). Notably, the ubiquitin-associated (UBA) domain is also 
essential for the function of p62 (Moscat et al., 2007).
p62 is easily spotted in cytosolic cellular speckles, or aggre-
gates, formed of PB1-driven p62 oligomers and p62-aPKC com-
plexes, as well as polyubiquitin-conjugated proteins (Sanz et al., 
2000; Moscat et al., 2006; Pankiv et al., 2007; Jin et al., 2009). These speckles are signal-organizing centers where p62 interacts 
with TRAF6 and caspase-8 (Jin et al., 2009; Sanz et al., 2000). 
TRAF6 is a lysine 63 (K63) E3 ubiquitin ligase involved in NF-κB 
activation (Moscat et al., 2006). Importantly, the interaction of p62 
with TRAF6 promotes its oligomerization and subsequent activa-
tion, which leads to K63 polyubiquitination of TRAF6 resulting in 
the activation of NF-κB (Sanz et al., 2000; Moscat et al., 2006).
p62 mutations are associated with Paget’s disease of bone 
(PDB) (Laurin et al., 2002), a genetic disorder characterized by 
enhanced osteoclastogenic activity, and mice with altered p62 
activity display bone phenotypes consistent with effects on 
osteoclasts (Duran et al., 2004; Kurihara et al., 2007; Hiruma 
et al., 2008; Laurin et al., 2002). Interestingly, mice lacking 
TRAF6, like those lacking p62, are characterized by defective 
osteoclastogenesis (Moscat et al., 2006). In addition, trans-
genic and knockin mice expressing the PDB mutation in p62 
display increased NF-κB signaling and have a tendency toward 
enhanced osteoclastogenesis. These findings validate the rel-
evance of a RANK-p62-TRAF6-NF-κB axis to human physiol-
ogy (Figure 1B) (Hiruma et al., 2008; Kurihara et al., 2007).
The ability of p62 to oligomerize and aggregate serves to 
catalyze the efficiency of TRAF6 effects, which requires the 
TRAF6-binding domain of p62 as well as its UBA and PB1 
domains (Moscat et al., 2006). Therefore, during IL-1 stimulation 
p62 recruits a TRAF6-IRAK complex to the cytosolic speck-
les consisting of small aggregates where polyubiquitin-linked 
signaling is efficiently activated to achieve NF-κB stimulation 
(Sanz et al., 2000). These p62-TRAF6 signaling hubs can also 
be involved in cell-signaling regulation through the modulation 
of receptor trafficking (Geetha et al., 2005).
Interestingly, the mechanism of action of death receptors 
DR4 and DR5 also needs p62 for optimal function. Thus, cell 
activation by TRAIL promotes the polyubiquitination of cas-
pase-8 through a cullin-3-dependent process (Jin et al., 2009). 
Notably, p62 associates with polyubiquitinated caspase-8, 
and its recruitment to oligomeric speckles is required to trigger 
the apoptotic pathway (Jin et al., 2009). This suggests that the 
p62 speckles are signaling hubs that could determine whether 
cells survive, by triggering the TRAF6-NF-κB pathway, or die, 
by activating the aggregation of caspase-8 and its downstream 
effector caspases.Cell 137, June 12, 2009 ©2009 Elsevier Inc. 1001
Control of p62 by Autophagy
The fact that p62 binds the autophagy regulator Atg8/LC3 
through a region termed the LC3-interacting region (LIR) (Fig-
ure 1A) combined with the observation that p62 accumulates in 
autophagy-deficient mice suggests a link between autophagy 
and p62 (Komatsu et al., 2007). p62 along with its PB1 part-
Figure 1. Cellular Functions of p62
(A) Structural domain organization of p62 and p62-interacting partners. p62 
has a PB1 domain, a ZZ-type zinc finger domain, a TRAF6-binding (TB) do-
main, an LC3-interacting region (LIR), and a ubiquitin-associated domain 
(UBA). 
(B) p62 speckles promote the oligomerization of TRAF6 and caspase-8 lead-
ing to the enhancement of NF-κB activation and apoptosis, respectively. p62 
speckles also sequester active ERK, restraining adipogenesis. 
(C) Autophagy deficiency in apoptosis-impaired tumor cells leads to increased 
p62 aggregation. This triggers a positive feedback loop for the generation of reac-
tive oxygen species (ROS) and enhanced genomic instability and tumorigenesis. 
(D) Ras-induced transformation promotes the accumulation of p62, which 
leads to an increase in NF-κB activity, thereby restraining ROS production 
and inhibiting tumor cell death. 
DISC, death-inducing signaling complex; ER, endoplasmic reticulum.1002 Cell 137, June 12, 2009 ©2009 Elsevier Inc.ner, NBR1 (neighbor of BRCA1 gene 1), have been proposed 
to regulate the packing and delivery of polyubiquitinated, 
misfolded, aggregated proteins and dysfunctional organelles 
for their clearance through autophagy in mammalian cells 
and in the fruit fly Drosophila (Kirkin et al., 2009; Nezis et al., 
2008; Kim et al., 2008; Pankiv et al., 2007). This new role for 
p62 could also regulate cell survival, as the disposal of toxic 
aggregates is essential for the prevention of cell death in sev-
eral pathological situations in which p62 is a component of 
these aggregates (Zatloukal et al., 2002). Mice lacking Atg7 are 
impaired in autophagy, leading to the appearance in the brain 
and liver of polyubiquitinated aggregates that colocalize with 
p62 (Komatsu et al., 2007). In mice lacking both Atg7 and p62, 
these aggregates are completely absent, suggesting that p62 
plays a structural role in their formation (Komatsu et al., 2007). 
This indicates that p62, in addition to its role as a signaling hub 
whose levels can be regulated by autophagy, may also be a 
central element in a quality-control mechanism for the disposal 
of toxic aggregates. However, this model presents a number of 
apparent inconsistencies that need to be resolved.
First, recent data demonstrate that the proteasome is also 
inhibited in autophagy-deficient cells due to the accumulation 
of p62 (Korolchuk et al., 2009). This might reduce the degrada-
tion of polyubiquitinated proteins, resulting in the appearance 
of polyubiquitinated aggregates—not as a consequence of a 
structural role for p62 but because of impaired proteasome 
activity (Korolchuk et al., 2009). However, if p62 expression 
is ablated in autophagy-deficient cells, the proteasome is not 
inhibited, the accumulated polyubiquitinated proteins are effi-
ciently degraded, and aggregates do not form (Korolchuk et 
al., 2009). This might explain the lack of aggregates in the mice 
lacking both Atg7 and p62 without invoking a role for p62 in 
building up the aggregates (at least in liver, in which the accu-
mulation of polyubiquitinated proteins in the double knockout 
mice is lower than that found in mice deficient in only Atg7) 
(Komatsu et al., 2007). The second problem with p62 being a 
“garbage disposer” of toxic aggregates is the nature of those 
aggregates. It is believed that by forming these aggregates 
p62 concentrates toxic misfolded proteins for two purposes: 
(1) to remove them from the soluble fraction, thus reducing their 
toxicity and (2) to direct these “packaged” aggregates to the 
degradative route. If the role of p62 is to remove these “toxic 
assets,” then more liver damage would be expected in mice 
deficient in both Atg7 and p62 than in mice only deficient in 
Atg7. Surprisingly, however, the loss of p62 lessens the liver 
damage caused by deficient autophagy in Atg7 knockout mice 
(Komatsu et al., 2007). One possible explanation for these find-
ings is based on the role of p62 in activating the caspase path-
ways (Jin et al., 2009). If liver toxicity associated with impaired 
autophagy leads to caspase activation and apoptosis, the loss 
of p62 in Atg7-deficient livers could dampen caspase-activated 
apoptosis. This could explain why the livers of Atg7/p62 double 
knockout mice are healthier than those in mice deficient in Atg7 
alone. Detailed biochemical analysis of livers from mice lack-
ing both Atg7 and p62 should shed light on this question. In 
any case, clarifying the nature and composition of these aggre-
gates and their relation to the p62 signaling speckles detected 
in cells activated by IL-1 or TRAIL is necessary for a better 
understanding of the quality-control mechanisms that go awry 
in cells with impaired autophagy or proteasome function. Such 
studies would lead to a better understanding of the pathologi-
cal situations characterized by the formation of p62-containing 
protein aggregates (Zatloukal et al., 2002).
p62, a Critical New Player in Cancer
The findings of Mathew et al. (2009) provide evidence that 
impaired autophagy leads to p62 accumulation, thereby pro-
moting tumorigenesis. This study grew from the paradoxical 
observation that autophagy is generally considered a survival 
pathway in cells undergoing nutrient deprivation; however, allelic 
loss of the autophagy gene beclin1 occurs in human tumors 
and favors carcinogenesis in mice (Mathew et al., 2007). In 
prior work, White and coworkers have suggested that a poten-
tial explanation for this conundrum is that, under conditions 
of aggressive tumorigenesis associated with metabolic stress, 
autophagy may prevent genome instability thereby restraining 
tumorigenesis (Mathew et al., 2007). Importantly, in autophagy-
deficient and apoptosis-incompetent tumor cells, metabolic 
stress leads to the accumulation of p62, elevated expression of 
endoplasmic reticulum (ER) chaperones, damaged mitochon-
dria, and reactive oxygen species (ROS) (Mathew et al., 2009). 
This increase in p62 levels is critical for tumorigenesis, as over-
expression of p62 in their cell model leads to increased tumor 
volume in mouse xenograft experiments (Mathew et al., 2009) 
(Figure 1C). These results are consistent with previous reports 
demonstrating that p62 is required for Ras-induced tumori-
genesis in vitro and in vivo (Duran et al., 2008). In these stud-
ies, it is shown that Ras-induced transformation is impaired 
in immortalized embryo fibroblasts from p62-deficient mice 
due to a decrease in NF-κB activation (Figure 1D). Interestingly, 
p62 transcription is induced in the Ras transformants through 
a mechanism that involves ERK and PI-3 kinase, two bona fide 
downstream targets of Ras, and the AP1 element in the p62 
promoter (Duran et al., 2008). The reduced NF-κB activation 
observed in the p62-deficient cells leads to lower levels of 
ROS scavengers, which results in enhanced ROS levels and 
more apoptosis. This could explain the reduced carcinogenic 
potential of p62-deficient cells (Duran et al., 2008). These cell-
culture studies are validated in a mouse model of cancer that 
closely mimics human lung adenocarcinoma. In these mice, 
oncogenic Ras is inducibly expressed in type II alveolar epithe-
lial cells. Consistent with the data from embryo fibroblasts, the 
lack of p62 completely abrogates Ras-induced lung adeno-
carcinomas and, importantly, inhibits the Ras-induced nuclear 
translocation of NF-κB in the lung cells in vivo (Duran et al., 
2008). The mechanism whereby p62 channels Ras signals to 
NF-κB involves the activation of TRAF6 (Figure 1D). This sug-
gests that Ras, by inducing the expression of p62, utilizes a 
pathway designed for the activation of NF-κB by RANK and 
IL-1 signaling to increase the survival of tumor cells by reduc-
ing damage due to Ras-activated ROS (Duran et al., 2008). 
These results, combined with observations that p62 levels are 
increased in at least 60% of human lung adenocarcinomas and 
in 90% of human lung squamous cell carcinomas (M.T.D.-M. 
and J.M., unpublished data), support a role for p62 in lung tum-
origenesis.The recent report of Mathew et al. adds a number of inter-
esting twists to the role of p62 in cancer. These investigators 
show that when cells with impairment in both apoptosis and 
autophagy are metabolically stressed, the accumulation of 
p62 leads to enhanced tumorigenicity through an as yet unde-
fined mechanism involving increased aneuploidy (Mathew et 
al., 2009). These observations place p62 as the missing link 
between deficient autophagy and increased tumorigenesis 
through the control of genome instability (Mathew et al., 2007). 
An interesting feed-forward loop may contribute to this pro-
cess. The increased ROS production in these cells might be 
responsible, at least in part, for the induction of p62 expres-
sion. p62 overexpression then contributes to additional ROS 
production as part of an amplifying loop, thereby promoting 
genome instability (Figure 1C) (Mathew et al., 2009).
A puzzling aspect of these studies is that the overex-
pression of p62 correlates with reduced NF-κB activation 
(Mathew et al., 2009). In contrast, other work has shown that 
activation of NF-κB is a consequence of p62 overexpression 
or activating PDB mutations in vitro and in vivo (Duran et al., 
2004; Kurihara et al., 2007). Moreover, a lack of p62 reduces 
NF-κB stimulation in Ras-transformed embryo fibroblasts 
and in the mouse model of Ras-induced lung adenocarci-
noma (Duran et al., 2008). Also, in the lung and fibroblast 
models, the lack of p62 leads to increased ROS due to inhib-
ited NF-κB (Duran et al., 2008) (Figure 1D), whereas the oppo-
site is found in the immortalized baby mouse kidney (iBMK) 
cell system utilized by Mathew et al. The reasons for this 
apparent discrepancy are unclear. One important difference 
is that the Ras-transformed cells were cultured with plentiful 
nutrients and with the autophagy and apoptosis pathways 
intact (Duran et al., 2008). It is plausible that when cells are 
deprived of nutrients and oxygen, and p62 overexpression 
reaches a certain threshold level, NF-κB is inhibited by the 
mopping up of critical components of the NF-κB pathway 
into huge p62 aggregates. These stand in contrast to the 
smaller p62-positive speckles (Sanz et al., 2000), which acti-
vate NF-κB. A similar scenario has been proposed to explain 
how p62 sequesters and inhibits the kinase ERK, which has 
repercussions for the roles of both proteins in adipogenesis 
and obesity (Rodriguez et al., 2006). The surprising inhibitory 
effect of p62 on NF-κB might also be related to the fact that 
the lack of autophagy does not result in the accumulation of 
polyubiquitinated proteins in the modified iBMK tumor sys-
tem (Mathew et al., 2009), whereas polyubiquitinated pro-
teins do accumulate in other in vivo systems (Komatsu et 
al., 2007). It is possible that iBMK tumor cells have evolved 
mechanisms to prevent increased polyubiquitination that, in 
the case of p62 and TRAF6, has been shown to be essential 
for NF-κB activation.
The cell system utilized by Mathew et al. is valuable because 
it could mimic a tumor that is experiencing nutrient and oxy-
gen deprivation, and in which the apoptosis and autophagy 
pathways are inhibited. However, it is clear that the loss of 
p62 correlates with decreased NF-κB activation in pneumo-
cytes expressing oncogenic Ras (Duran et al., 2008). This is 
true for embryo fibroblasts and osteoclasts as well, strongly 
supporting a role for p62 as a physiologically relevant activa-Cell 137, June 12, 2009 ©2009 Elsevier Inc. 1003
tor of NF-κB. Further studies should clarify how p62 switches 
from an activator of NF-κB to an inhibitor under conditions of 
metabolic stress.
The fact that the modified iBMK cells have blunted apoptosis 
also precludes a test of the role of p62 in caspase activation in 
cancer, as demonstrated by Jin et al. (2009). It is possible that 
in tumor cells with intact apoptosis pathways, p62 serves to 
fine-tune the balance between antiapoptotic and proapoptotic 
signals. This subtle homeostatic process might be completely 
subverted when autophagy genes are lost or when autophagy 
is inhibited as a consequence of hyperactivation of the PTEN/
Akt/TOR pathway. Another example would be organs, such as 
the liver, in which compensatory proliferation in the presence 
of an inflammatory response might convert a tumor-promoting 
signal, like NF-κB, into a tumor-suppressor pathway. The role 
of p62 in the disposal of damaged organelles and misfolded 
proteins in aberrantly growing tumor cells are additional ques-
tions to consider.
The exciting recent observations establish p62 as a potential 
therapeutic target in at least some types of cancer. These find-
ings also expose the need for further investigation concern-
ing the role of p62 in tumorigenesis, given that different gene 
mutations, cell types, and environmental conditions appear to 
dramatically influence its effects.
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